Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of $87.00. The company’s shares closed yesterday at $57.73.

$60,000 of INCYTE CORPORATION lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education around access to innovative ...

Talent from Kerala shared her disturbing on-set experience with a lead actor using drugs Malayalam actress Vincy Aloshious has made it clear she will not act alongside colleagues who use drugs ...

"It's been great. We've been shooting a lot of crazy sequences. The crew is crushing it, and the action is nonstop," said Amanat to Marvel.com. As for Fisk, the producer added, "I'm very excited ...

The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12.12% in the S&P 500 index, rose 0.09% so far this year, compared to 8. ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. As the U.S. stock market navigates the complexities of trade ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry. MADISON, Wis., April 01, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading ...